NKTR - Nektar Chief Medical Officer Brian Kotzin CFO Jillian Thomsen to step down

2023-04-18 03:12:29 ET

• As part of the reorganization initiative , Nektar ( NASDAQ: NKTR ) also announced several changes to its executive team: Dr. Brian Kotzin, Nektar's Chief Medical Officer, will be stepping down from his full-time role but will continue to serve in an ongoing role as a strategic advisor to the company. Dr. Mary Tagliaferri, current Chief Development Officer, will assume the role of Chief Medical Officer.
• Jillian Thomsen will be stepping down from her role as Chief Financial Officer and will depart the company in June following a transition period. The company has appointed Sandra Gardiner to the role of acting CFO. She is a partner at FLG Partners, a leading CFO services firm in Silicon Valley.
• Kevin Brodbeck, Nektar's SVP of Technical Operations, will depart the company in June following a transition period. Ken Franke, current VP of Biologics Development & Manufacturing will assume Kevin's responsibilities.
• As of March 31, 2023, the Company had cash, cash equivalents, and marketable securities of approximately $456 million and the 2023 Restructuring Plan is intended to extend the Company’s cash runway into the middle of 2026.
• Seeking Alpha's Quant Rating has viewed Nektar ( NKTR ) as a strong sell since Feb. 16.
• Shares of NKTR are up 3.75% after-hours on Monday to $1.02.

For further details see: